3 ms·
I would have to say that not much is the result of pure bureaucratic inefficiency. The extensive clinical trials are there for a reason, and that is to prevent
by iplaw 9y ago
I would have to say that not much is the result of pure bureaucratic inefficiency. The extensive clinical trials are there for a reason, and that is to prevent the release of thalidomide-like pharmaceuticals. Researching, developing, and vetting failed candidates is also a major cost that must be recouped via the drugs successfully brought to market. The actual costs associated with bureaucratic inefficiencies are nil in comparison.
[1]: https://en.wikipedia.org/wiki/Cost_of_drug_development#Research_and_development https://en.wikipedia.org/wiki/Cost_of_drug_development#Resea...
- everybodyknows 9y agoAre FDA vetting standards really uniform across all drugs, from children's vaccines, to last-resort therapies for the terminally ill? The latter surely have little to lose in taking a risky drug -- if they can afford it.
- fellellor 9y agoI'm still not convinced.